Adult-type Diffuse Gliomas

1 clinical trials · Condition

Record	Firm	Date
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (NCT05267106)	Incyte Corporation	2022-05-20

Every clearance here is in the API, with alerts when new ones post.